Media
Position Statement
Epilepsy Scotland provide position statements on the issues that affect people with epilepsy. This section will be updated on a regular bases
Should you require further information on the position statements please Allana Parker on 0141 419 1701 or email aparker@epilepsyscotland.org.uk
New drug for childhood epilepsy
A new drug Inovelon (rufinamide) has been licensed to help children with Lennox-Gastaut Syndrome. This severe form of epilepsy is difficult to treat. Children with Lennox-Gastaut Syndrome can have severe seizures and injuries caused by drop attacks. In research trials this new drug reduced seizures by as much as 42%.
Keppra and the Scottish Medicines Consortium
Scottish Medicines Consortium has issued guidance today restricting the use of Keppra in Scotland. Epilepsy Scotland understands that Keppra is still available and people who are already prescribed the drug should continue to get it.
Managing Long Term Conditions - Audit Scotland Report
Audit Scotland has prepared a report on how the NHS manages long term conditions like epilepsy. Read more>>
Consistency of Supply ( Brand versus generic medication)
Antiepileptic drugs are known by two names – a brand and a generic name and there can be subtle variations between brand preparations which could affect seizure control. Read more>>
Anyone of us with suspected epilepsy expects an expert diagnosis as soon as possible – you don’t want your life put on hold or put at risk from untreated seizures. Read more >>
Lamotrigine and hormonal contraceptives
Women are worried about recent research which suggests that the antiepileptic medication lamotrigine can make the contraceptive pill less effective.